Drug intelligence / Profile preview

teglitazide

Development stage: Unknown
Lead developer: Henan University
Modality: Small Molecules
Administration: Intravenous

Overview

Teglitazide is a pharmaceutical agent currently under clinical investigation for the prevention of postoperative nausea and vomiting (PONV) and the management of postoperative pain. It is being evaluated in prospective, parallel-group interventional studies, particularly in high-risk female patients undergoing elective gynecological laparoscopic surgery. In these clinical settings, teglitazide is compared against standard opioid-based patient-controlled analgesia (PCA), such as sufentanil, to assess its efficacy in reducing PONV, improving recovery quality (as measured by the QoR-15 scale), and facilitating gastrointestinal recovery. The drug is developed by researchers at Henan University and Huaihe Hospital.

Other names: teglitazide

Beyond the preview

Go deeper on teglitazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on teglitazide.

Explore the full profile